Sichuan Cancer Hospital And Research Institute

This study is testing if adding an immunotherapy drug (tislelizumab) to standard chemotherapy helps people with a specific type of esophageal cancer that is at high risk of returning. It involves 80 participants whose cancer did not fully disappear after initial chemo and radiati…